---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-294613"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2026-07-02T20:20:52+00:00"
generated_at: "2026-07-02T20:22:09.431145+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology raises $50M upfront in private placement; warrants could add $64M

## Summary
- Gross proceeds of ~$50M from 19.6M shares at $2.551/share; warrants at $3.289 for additional ~$64M if exercised.
- Financing led by BVF Partners with GordonMD, RTW Investments, Coastlands Capital; expected close July 2, 2026.
- Proceeds extend cash runway into Q2 2027; support MICVO Phase 1 monotherapy and Phase 1/2 combination studies.
- Updated Phase 1 monotherapy data for 2L+ R/M HNSCC expected Fall 2026; Phase 1/2 combo data in Q4 2026.
- Warrants exercisable upon earlier of public disclosure of MICVO Phase 1 data or Oct 1, 2026; expire July 2, 2029.

## SEC filing metadata
- accession: 0001193125-26-294613
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2026-07-02T20:20:52+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312526294613/0001193125-26-294613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312526294613/pyxs-20260630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-294613
- JSON: https://secwatch.observer/filing/0001193125-26-294613.json
- Plain text: https://secwatch.observer/filing/0001193125-26-294613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.